Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Myelin Oligodendrocyte Glycoprotein–Associated Disorders

1 Aug 2022

Abstract excerpt

PURPOSE OF REVIEW: Anti-myelin oligodendrocyte glycoprotein (MOG) autoantibodies have become a recognized cause of a pathophysiologically distinct group of central nervous system (CNS) autoimmune diseases. MOG-associated disorders can easily be confused with other CNS diseases such as multiple sclerosis or neuromyelitis optica, but they have a distinct clinical phenotype and prognosis. RECENT FINDINGS: Most...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoimmune Neurological Disorders and Treatments
Share to Multiple Sclerosis Research Studies
Share to Peripheral Neuropathies and Disorders

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35938661
DOI: 10.1212/con.0000000000001127

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Myelin Oligodendrocyte Glycoprotein–Associated DisordersPMID 35938661Read ↗

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): Pathophysiology, Clinical Patterns, and Therapeutic Challenges of Intractable and Severe FormsSemantic proximity Read ↗

Assessment of international MOGAD diagnostic criteria in patients with overlapping MOG-associated disease and multiple sclerosis phenotypes.Semantic proximity Read ↗

MOGAD update: new phenotypes in the expanding clinical spectrum.Semantic proximity Read ↗

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Insights into pathogenesis and biomarkers of prognosisSemantic proximity Read ↗

The Potential Pathogenicity of Myelin Oligodendrocyte Glycoprotein Antibodies in the Optic PathwaySemantic proximity Read ↗

Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating DiseasesSemantic proximity Read ↗

Epidemiological and clinical characteristics of myelin oligodendrocyte glycoprotein antibody-associated disease in a nationwide surveySemantic proximity Read ↗

Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.Semantic proximity Read ↗

Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotypeSemantic proximity Read ↗

Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination.Semantic proximity Read ↗

E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.Semantic proximity Read ↗

Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.